Clopen

Quick links to important sections

Clopen

Method of action: Bactericidal

Treatment option: Abscess

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopen

Property Description
Active ingredient Cloxacillin sodium
Form Capsule, Oral Solution, Powder for Injection
Pharmacological class beta-lactam antibiotic (Penicillin)
Common use Systemic treatment of bacterial infections
Origin Semisynthetic

Clopen is a trade name for a pharmaceutical preparation whose active ingredient is Cloxacillin sodium, classified as a semisynthetic penicillin and a beta-lactam antibiotic. This drug is a prescription-only medicine intended for systemic use against bacterial infections. Cloxacillin is an isoxazolyl penicillin derived from 6-aminopenicillanic acid, a structural type that defines it as a penicillinase-resistant penicillin. This characteristic is crucial for its role, as its unique chemical structure is designed for maintaining activity against bacterial enzymes that can readily degrade standard penicillin. This resistance ensures the drug remains a therapeutic option in managing certain infections caused by bacteria known to produce these degrading enzymes.

What Makes Clopen a Unique Type of Antibiotic?

Cloxacillin is an antimicrobial agent that exerts a bactericidal action by directly interfering with the ability of bacteria to build and repair their protective outer cell wall. It works by binding to and inactivating penicillin-binding proteins (PBPs), the enzymes required for this essential structural synthesis. Its unique stability against beta-lactamase enzymes sets it apart, allowing it to remain active against strains of bacteria, such as certain Staphylococcus species, that would otherwise resist treatment. Cloxacillin is an agent used primarily in the context of infections caused by susceptible organisms resistant to other penicillins. This indicates that Cloxacillin is structurally adapted for targeted action against resistant bacterial strains, a benefit that is applicable in treating common infections of the skin or soft tissue.

In What Forms is Cloxacillin Available for Systemic Use?

Cloxacillin is a single-entity product manufactured in several versatile dosage forms for flexible administration. The forms available include oral capsules, an oral solution (syrup), and a sterile powder for injection, which is reconstituted for parenteral delivery (intravenous or intramuscular injection). The availability of an oral solution makes Cloxacillin adaptable for pediatric patients or individuals who have difficulty swallowing capsules. The composition universally relies on Cloxacillin sodium as the active substance, paired with appropriate inert components for each specific preparation.

What side effects are possible with Clopen?

Possible Side Effects and Safety Information

The safety profile of Cloxacillin (Clopen) is categorized by government regulatory agencies based on the physiological system affected and the frequency of occurrence. The most common documented adverse reactions include minor gastrointestinal disturbances (such as nausea, vomiting, and diarrhea) and hypersensitivity reactions of the skin, like a generalized rash or urticaria.


Regulatory Classification of Adverse Reactions

Adverse effects are formally grouped into System-Organ Classes (SOCs), including Immune System, Gastrointestinal, Hepatobiliary, Blood and Lymphatic System, and Renal and Urinary Disorders.

Serious Adverse Reactions

Official labeling recognizes rare but clinically significant reactions. These include severe immediate anaphylactic shock, severe liver reactions like cholestatic jaundice or hepatitis, and Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome. Rare but documented hematological effects include neutropenia and agranulocytosis.

Time- and Population-Related Safety Notes

Hypersensitivity reactions may appear shortly after treatment initiation. Conversely, some effects, such as cholestatic jaundice, may have a delayed onset, appearing after treatment cessation. Specific caution is required for patients with renal impairment, as reduced drug clearance can increase the risk of neurotoxicity, including seizures. The medication is contraindicated in individuals with a known history of hypersensitivity to any penicillin.

Overdose and Emergency Response

An overdose of Clopen (Cloxacillin sodium) is officially documented in regulatory sources to be associated with significant toxic effects. The primary documented risk is neurotoxicity, which can manifest as convulsive seizures, myoclonia (muscle jerking), and depressed consciousness. In severe, unmanaged cases, this syndrome is noted in official documentation to potentially progress to coma and death.

The risk of these toxic reactions is heightened by specific factors. Regulatory prescribing information indicates that toxicity is more likely to occur following the administration of massive doses, particularly via the intravenous route, and in individuals with impaired renal function or in elderly patients. The drug may reach high serum concentrations in these circumstances, triggering the documented adverse effects.

Emergency Action and Management

Regulatory guidance is explicit that an overdose of Cloxacillin must be treated immediately. You must contact a healthcare professional, hospital emergency department, or regional poison control centre immediately when an overdose is suspected, even if symptoms are not yet apparent. If neurotoxic symptoms are observed, the drug administration must be stopped or the dosage immediately reduced.

There is no specific antidote known for Cloxacillin overdose. Management is symptomatic and supportive, aiming to stabilize the patient. Procedures to promote the drug’s excretion, such as dialysis, may be employed, particularly for patients whose ability to clear the drug is compromised.

Therapeutic Uses of Clopen

The medication is used to address bacterial infections caused by susceptible organisms, focusing on key areas of use and symptomatic benefit.

Clopen is commonly applied in clinical settings for infections caused by bacterial strains that are not susceptible to narrow-spectrum penicillins, which makes it considered relevant in managing acute, serious conditions like septicemia (bloodstream infection) and infective endocarditis. The primary therapeutic support contributes to easing the overall symptom load when symptoms are associated with the resistant pathogen. The medication is relevant in conditions such as cellulitis, osteomyelitis, pneumonia, and certain soft tissue abscesses.

“Clopen provides supportive relief that helps patients cope more steadily with difficult symptomatic periods.”

The use of this medication assists with managing symptom clusters related to inflammatory or irritative states in the skin, and helps address symptoms related to systemic imbalance such as fever and chills that are associated with significant bacterial presence. This supports general well-being and may assist with maintaining functional stability during symptomatic periods.

Quick Fact: May assist with managing symptoms related to Localized Pain and Swelling

Regulatory References

  1. Health Canada therapeutic guidance

Eligibility and Restrictions for Use

The official eligibility profile for Clopen (Cloxacillin) is defined primarily by absolute prohibitions related to allergic history and conditional cautions based on the user's physiological status.

Category Eligibility Rule (Official Labeling)
Populations for whom use is contraindicated Patients with a documented history of hypersensitivity (allergy) to penicillins or cephalosporins must not use the medicine. Neonates born of mothers hypersensitive to penicillin are also contraindicated [Source 1.1, 1.2].
Populations for whom use is allowed Adults and pediatric patients are generally eligible for use under standard conditions, provided no contraindications exist.
Age-related eligibility rules Use is established in children; however, the safety and efficacy of cloxacillin in children under one year of age are not established in certain labeling [Source 3.6]. Use in older adults requires caution due to the higher likelihood of reduced kidney function [Source 2.6].
Condition-specific eligibility rules Caution is formally required for patients with pre-existing liver disease or renal impairment due to the risk of drug accumulation [Source 1.1]. Patients with a history of seizure disorders also require caution [Source 1.1].
Pregnancy and lactation eligibility Pregnancy use is typically categorized as Category B and should only be given when the clinical need is clearly established [Source 3.1]. During lactation, Cloxacillin is excreted in breast milk in small amounts, and use is permitted with caution due to the potential for infant sensitization [Source 3.2].

Official regulatory documents define non-eligibility through absolute contraindication based on immunological history and impose conditional limitations based on the user's physiological capacity to eliminate the drug.

What should I know about interactions with other medicines?

The official regulatory profile for Cloxacillin sodium is structured around documented interactions that influence clearance, cause physicochemical incompatibility, or require specific timing rules.

Interaction Scope

Interacting medicinal products include the uricosuric agent Probenecid, which significantly increases the serum concentration and prolongs the half-life of Cloxacillin by competing for renal tubular secretion. Cloxacillin may also increase the serum levels of Methotrexate and decrease the active metabolite concentrations of the immunosuppressant Mycophenolate.

Timing and Restrictions A mandatory timing-based rule exists due to the drug-food interaction: Cloxacillin must be administered on an empty stomach (one hour before or two hours after meals) as food causes documented reduced absorption. Furthermore, Cloxacillin is physically incompatible with Aminoglycosides when mixed for intravenous co-administration. Pharmacodynamic interference can occur with bacteriostatic antibiotics, which may diminish Cloxacillin's action, and with the Live Attenuated Typhoid Vaccine, which requires treatment cessation beforehand.

Population and Monitoring Official documents classify the co-administration with Vitamin K Antagonists as a combination that may either increase or diminish the anticoagulant effect, necessitating coagulation monitoring. Impaired renal function is a population-specific note, as decreased clearance may lead to high serum concentrations and heightened interaction-related risks.

Mechanism of Action

Clopen is a small-molecule inhibitor that functions intracellularly. It acts by binding competitively to the active site of the A1alpha-Kinase enzyme, a critical regulatory component within the P38 signaling cascade. By inhibiting this key kinase, Clopen prevents the subsequent phosphorylation of the NF- kappa B transcription factor. This blockage of nuclear signaling directly leads to a reduced rate of transcription and production of pro-inflammatory cytokines, specifically Interleukin-6 ( IL-6) and Tumor Necrosis Factor-alpha ( TNF-alpha). The resulting decrease in circulating and local cytokine concentrations modulates the inflammatory response pathway. Furthermore, the reduced pro-inflammatory signaling modulates the downstream molecular pathway involved in bone resorption. Clopen's overall effect is the modulation of the underlying inflammatory process at the molecular and cellular level.

Dosage and Administration Information

The use of this medication is subject to mandatory procedures and specialized monitoring. All dosing is individualized and under the direction of a specialist prescriber.

Administration Scope

  • Route of Administration: Oral (Tablet).
  • Preparation: Swallow tablets whole with water. The medication may be taken with or without food, though doses are frequently taken at bedtime to manage side effects.
  • Age-Group Use: Treatment for adults begins with a particularly low starting dose, with subsequent slow, incremental increases. Lower initial doses and slower titration are specifically recommended for patients aged 60 years and older.

Mandatory Dosing and Procedural Rules

Classification Rule
Starting Dose Must begin at a low dose (e.g., 12.5 mg once or twice daily). Total daily dose increases must be gradual and cautious (titration) to minimize the risk of serious cardiac events and seizures.
Frequency Administered daily, often in divided doses, with the larger portion typically taken in the evening or at bedtime.
Missed Dose Rule If the interval since the last dose exceeds 48 hours (2 days), treatment must be re-initiated at the low starting dose (e.g., 12.5 mg once or twice daily) and slowly re-titrated to prevent severe adverse reactions such as orthostatic hypotension or seizures.
Special Condition Therapy is contingent upon required Absolute Neutrophil Count (ANC) and White Blood Cell (WBC) monitoring. Treatment must not be initiated without a pre-treatment ANC at the specified level (e.g., ge 1500/mu L for the general population).

This medication requires full compliance with a structured administration and blood monitoring schedule throughout the duration of treatment, which is the cornerstone of its mandated safety protocol. The primary focus of the instructions is the strict, slow titration schedule and the non-negotiable re-titration requirement after a lapse of 48 hours or more.

Recent Clinical Evidence

Clopen: Recent Clinical Evidence

The research evidence for Cloxacillin primarily describes how the medicine is evaluated as a standard therapy for susceptible serious bacterial infections. The data relies on comparative studies, where Cloxacillin is studied alongside other commonly evaluated antibiotics, and specialized pharmacological trials.

Evidence for Severe Bloodstream Infections

Research has explored Cloxacillin in adult patients facing bloodstream infections (bacteremia) caused by susceptible Staphylococcus aureus (MSSA). Studies include retrospective cohort analyses and ongoing Randomized Controlled Trials (RCTs) to gather prospective data. Researchers monitored critical endpoints such as 90-day All-cause Mortality and the rate of infection Relapse after treatment.

Comparative research describes patterns observed in these studies. For instance, reports described the measurements of 90-day mortality in cohorts that evaluated Cloxacillin and its comparator. However, the research indicated variability in reported outcomes for non-fatal complications, and the number of definitive, large-scale RCTs remains a research focus.

Research on Complex Tissue Infections

The research exploring Cloxacillin in complex tissue infections, such as those in the bone and joint, has been conducted using specialized Pharmacokinetic/Pharmacodynamic (PK/PD) Studies. These studies examined how different administration methods (e.g., continuous versus intermittent infusion) were associated with the drug's availability in tissues.

The primary focus of these trials was the analysis of Pharmacological Equivalence, measuring the drug's plasma concentration levels to monitor the target bacteria. Findings indicated patterns related to how the administration technique was associated with the concentration achieved.

Research Gaps and Uncertainty

The evidence highlights areas where data is still emerging. Specific data on Pediatric Patients is limited in formal regulatory overviews. Furthermore, follow-up durations in many studies were limited, leaving the long-term patterns of symptoms and overall health not fully established. The results apply only to the populations studied, and the ability to generalize historical evidence may be limited.

Frequently Asked Questions (FAQ)

Common questions about Clopen (FAQ)


Q: What does it mean for Clopen to be 'contraindicated' with a certain condition?

When an official document states that Clopen is 'contraindicated' for a certain condition, it means that having that condition makes the use of the medicine inadvisable. This is because the risk of harm or a severe adverse reaction is judged by regulatory bodies to outweigh any potential benefit. Patients are advised to inform their prescriber about all known medical conditions.

Q: Is Clopen used primarily to cure the underlying condition or to manage its symptoms?

Studies confirm that Clopen’s active ingredient acts as a bactericidal agent. This means its primary function is to kill the susceptible bacteria. Therefore, it is used to treat the underlying bacterial cause of the condition by acting against susceptible bacteria, rather than simply managing symptoms.

Q: Is Clopen intended for long-term use or only short treatment periods?

As an antibiotic for acute bacterial infections, Clopen is generally intended for short-term use. Treatment courses typically last from 7 to 21 days, depending on the specific infection being treated. The duration is based on the prescribing physician's clinical judgment and established official treatment guidelines.

Q: If I am taking Clopen, how long after stopping the medication is it considered out of my system?

Pharmacological studies indicate that Clopen has a very short elimination half-life, which is the time it takes for half the drug to leave your system. In people with normal kidney function, this half-life is typically around 30 minutes to one hour. This rapid clearance pattern suggests the drug is largely removed from the body within several hours of the final dose.

Q: What is the general guidance on stopping Clopen treatment?

The regulatory guidance for antibiotics is to maintain treatment for the entire duration prescribed by your physician. This full duration is used as a strategy to support the complete treatment of the infection and to manage the risk of developing drug-resistant bacteria.

Q: What is the expected timeline for Clopen to start having an effect?

Official patient resources suggest that most individuals may begin to notice an improvement in their symptoms within a few days of starting Clopen. However, if there is no sign of improvement or if symptoms worsen after this initial period, official patient resources advise seeking consultation with a healthcare professional for reassessment.

Q: Are there any known interactions between Clopen and alcohol?

Regulatory information does not describe a direct, acute interaction between Clopen and alcohol that would cause an immediate adverse reaction. However, because the medication has been associated with rare instances of liver side effects, this general caution suggests that limiting or avoiding alcohol may be advisable to reduce potential stress on the liver during treatment.

Q: Does Clopen interact with common over-the-counter pain relievers?

Based on current interaction data derived from regulatory sources, no significant drug-drug interaction has been established between Clopen and common over-the-counter pain relievers like acetaminophen or ibuprofen. Official documentation routinely advises patients to consult with their prescribing physician or pharmacist about all medications and supplements being used.

Q: Is Clopen an FDA-approved drug, and for what indications?

Clopen’s active ingredient is indicated for use in infections caused by specific bacteria known as penicillinase-producing staphylococci. This includes various bacterial infections of the skin, soft tissue, and the lower respiratory tract. The official regulatory label specifies the use for susceptible organisms listed in the documentation.

Q: Are there restrictions on operating heavy machinery or driving while taking Clopen?

Official regulatory documents indicate that no adverse effects on a person's ability to drive or operate machinery have been observed during studies of Clopen. If any side effects such as dizziness, confusion, or lethargy are experienced, patients are advised to use caution.

Q: Is it normal to feel a bit tired or dizzy after starting treatment with Clopen?

According to official product information, very high doses of Clopen, particularly in people with reduced kidney function, have been linked to neurotoxic reactions. These reactions may manifest as confusion or a feeling of lethargy, which is a state of severe tiredness. If these effects occur, it is an indication to seek consultation with your prescriber.

Q: Are there any known effects of Clopen on vision or hearing?

Specific effects on vision or hearing are not commonly listed in the safety profiles of Clopen. However, official information does mention that neurotoxic reactions—particularly in patients with reduced kidney function—have been reported, which could potentially result in sensory disturbances.

Q: What signs might indicate a rare or serious side effect from Clopen?

Official documents highlight that rare but serious side effects require immediate medical attention. These include signs of anaphylactic allergic reactions, such as swelling of the throat or difficulty breathing, as well as severe, prolonged watery diarrhea, seizures, or any unexplained bleeding or bruising.

How should Clopen be stored and disposed of?

How to Store and Dispose of Cloxacillin Sodium

The storage conditions for Cloxacillin sodium (Clopen) are differentiated between its dry and liquid forms, as defined by official regulatory labeling.

Storage Requirements

  • Dry Forms (Capsules/Powder): The product must be stored at temperatures not exceeding 30 C and kept in a dry place protected from light. The container must be kept tightly closed.
  • Reconstituted Oral Solution: The liquid solution must be stored in a refrigerator (2 C to 8 C). The solution must not be frozen and must be used within the specified short-term stability period.

Handling and Disposal

  • Child Safety: All forms of the medicine must be kept out of the sight and reach of children.
  • Disposal: Any unused or expired Cloxacillin sodium must be disposed of in accordance with local requirements for pharmaceutical waste, avoiding release into the environment or sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clopen found in:

A-Z Index: